JG
Jerrold B Grossman (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in ADMA Biologics, Inc. (ADMA). Across 2 priced purchase filings, the average 21-session return was +3.1% from execution and +1.1% from disclosure (delay-adjusted; derived). The largest single filing was $100K of ADMA (12,500 sh × $8.01, as filed), executed May 12. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+3.1%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+1.1%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$200K
shares × price, as filed
Last traded
May 12
Filed May 14
Median ADV $38.1M across their filed names
Open performance→Volume by month
Buys $200K
Sells $213K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
ADMARecent filings
ADMAPURCHASE
ADMA Biologics, Inc.
View filing →
$100K12,500 sh × $8.01
Exec May 12
Filed May 14 · 7:00 AM ET ADMAPURCHASE ADMA Biologics, Inc. View filing → $100K
12,500 sh × $8.01
Exec May 11
Filed May 12 · 5:22 PM ET ADMASALE ADMA Biologics, Inc. View filing → $213K
10,000 sh × $21.31
Exec Jun 9 2025
Filed Jun 10 2025 · 5:30 PM ET